Portal Hypertension News

New data published in Hepatology showed that beta-blockers lowered portal pressure in patients with clinically significant portal hypertension, suggesting they could prevent decompensation of cirrhosis in this patient population.

Intrapulmonary vascular dilatations occurred more commonly in patients with portopulmonary hypertension and were associated with decreased overall survival, according to study data published in Liver Transplantation.

SAN FRANCISCO — A 28-day oral course of therapy with emricasan, a pan-caspase inhibitor, reduced portal pressure in patients with compensated cirrhosis and portal hypertension, according to Late Breaker data presented at The Liver Meeting 2015.

Conatus Pharmaceuticals Inc. announced results from its phase 2 clinical trial of emricasan, which showed reduced levels of hepatic venous pressure gradient in patients with liver cirrhosis and severe portal hypertension and reduced cleaved Cytokeratin 18 in patients with liver cirrhosis.

Kuvan was not more effective in reducing portal pressure in patients with cirrhosis and portal hypertension than placebo, according to new study data.

Portal vein thrombosis that developed in patients with cirrhosis did not lead to progression of liver disease, according to study data.

The Baveno V criteria accurately predicted outcomes of acute gastrointestinal bleeding in patients with portal hypertension, according to findings in a prospective study.

The presence of clinically significant portal hypertension in patients with cirrhosis increased mortality and decompensation after surgery for hepatocellular carcinoma, according to recent study data.

Pediatric patients with nonalcoholic fatty liver disease were more likely to have high blood pressure and persistent high blood pressure compared with children without nonalcoholic fatty liver disease, according to data from a new study.

BOSTON — In obese patients with cirrhosis and portal hypertension, a 16-week diet and moderate exercise intervention safely reduced hepatic vein pressure gradients, or HVPG, in addition to body weight, according to data presented at a plenary presentation at The Liver Meeting.